The first-of-its-kind partnership combines Splash’s recruitment platform with C2N’s innovative blood tests to accelerate clinical research and improve patient experience.
Splash Clinical, the new standard in trial enrollment, and C2N Diagnostics, LLC , a pioneer in advanced diagnostic testing for brain health, announced a partnership to improve recruitment efficiency for Alzheimer’s disease clinical trials throughout the United States and globally.
Under the partnership, Splash Clinical will provide a new clinical trial recruitment program that combines Splash’s proprietary recruitment infrastructure with C2N’s PrecivityAD2 blood tests.
PrecivityAD2 is an innovative, high accuracy blood test intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers and researchers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, and inform medical management and treatment decisions. Research has shown that PrecivityAD2 has comparable diagnostic performance to amyloid PET and CSF biomarker analysis.
Health Technology Insights: Recreate Behavioral Health of Ohio Gains Primary Mental Health License
Combining C2N’s Precivity biomarker platform with Splash’s infrastructure, this comprehensive pre-screening approach for clinical research applications aims to ensure patients are trial-ready, streamlining what is oftentimes a complex and multi-faceted pre-screening process. The result will enable more accurate and more efficient qualification of individuals for clinical trials, saving substantial time and expense for clinical trial sponsors.
“Our partnership with C2N Diagnostics is a step forward in our mission to transform clinical trial enrollment,” said Matt Teuteberg, CEO of Splash Clinical. “We believe by using C2N’s PrecivityAD2 blood tests in our platform, we can reduce screen failure rates, which often exceed 70% (Goldman et al., 2020) in Alzheimer’s trials, while saving valuable time and resources for our partners. In the end, this means getting potentially life-changing treatments to patients faster.”
The partnership includes a specialized patient concierge service that guides participants through the pre-screening process and coordinates PrecivityAD2 testing and trial participation, ensuring a smooth experience for both patients and sites while reducing time and resource demands. By developing an integrated solution, Splash aims to lower recruitment costs and timelines, maintain high-quality standards, and enable researchers to access a broader, more diverse population while ensuring participants meet trial criteria before site visits.
Health Technology Insights: Immunovia Releases Positive Data from VERIFI Pancreatic Cancer Test
“C2N Diagnostics prides itself on collaborating with the leading entities and researchers in the world to better understand the causes of Alzheimer’s disease as well as ways to better diagnose and treat it. This is why we’re excited to partner with Splash and its patient-centric platform focus,” said Dr. Joel Braunstein, C2N CEO. “C2N assays have been used in over 150 Alzheimer’s disease and other research studies, and we’re confident even more clinical trials will benefit as a result of this new initiative that seeks to ease recruitment and accuracy for all involved.”
The collaboration with C2N builds on Splash Clinical’s track record of successful partnerships in the Central Nervous System (CNS) space. Splash continues to offer sponsors and research organizations new tools to improve their enrollment in clinical trials while enhancing healthcare equity among study participants.
Health Technology Insights: Aura Introduces AI-Powered Tools to Take on Youth Mental Health Crisis
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobalNewswire
